A brand-new CDMO is pushing forward with plans to be a player in gene-based drug manufacturing with a new manufacturing facility in a U.S. biotech hub.
Lexington, MA-based Brammer Bio laid out its plans at the BIO International event in San Francisco, saying it will spend about $50 million to outfit and staff a 50,000-square-foot facility in its home city for production of late-stage and commercial-scale viral vector and cell-based therapies.
Brammer Bio expects the facility to be operating by Q2 of next year. The plan is to eventually add 200 employees to its workforce there.
Brammer Bio was formed in March through the merger of Brammer Biopharmaceuticals and Alachua, FL-based Florida Biologix, with the help of a capital infusion from Ampersand Capital Partners, Florida Biologix's majority owner.
"The Lexington facility will be equipped for largescale manufacturing with a focus on compliance in these emerging drug categories,” Richard Snyder, Brammer CSO, said in a statement.
The company also has 45,000 square feet of process development and Phase I/II clinical manufacturing space in Alachua, FL, and intends to double that.
As more and more of the specialty drugs being developed by biotech and pharma are gene-based therapies, Brammer joins Japan’s Fujifilm Diosynth Biotechnologies and others like Swiss CDMO Lonza, in hustling to build or expand facilities to manufacture them.
- read the announcement
Related Articles:
New player jumping into cell therapies manufacturing
Merck to outfit $60M biologics plant for Fujifilm to use